Consensus for FY25 revenue is $72.72M. The company also reiterated its FY25 adjusted operating expense guidance of $101M-$105M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences reports Q2 EPS (23c), consensus (28c)
- Sight Sciences Raises Full-Year Revenue Guidance
- Sight Sciences announces results of CUA assessing TearCare system
- Sight Sciences announces publication of 24-month results of SAHARA RCT
- Sight Sciences price target raised to $4 from $3 at Morgan Stanley